Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | LIG1 | P18858 | 1/20 | 0.45 |
| ▸ | C1S | P09871 | 13/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5982145 | 0.85 | PLAU (1.00) | PLAUPKMLIG1C1S | |
| Hydrochloric Acid SCHEMBL7855116 | 0.83 | PLAU (0.96) | PLAUPKMLIG1C1S | |
| SCHEMBL6926372 | 0.83 | — | — | |
| Trifluoroacetic Acid SCHEMBL5223272 | 0.72 | PLAU (0.72) | PLAUPKMLIG1C1S | |
| SCHEMBL8247302 | 0.66 | L3MBTL1 (0.37) | — | |
| SCHEMBL9436124 | 0.66 | PLAU (0.49) | PLAUPKMLIG1 | |
| SCHEMBL9436127 | 0.66 | PLAU (0.49) | PLAUPKMLIG1 | |
| SCHEMBL7205892 | 0.65 | F2 (0.52) | — | |
| SCHEMBL23553995 | 0.63 | PLAU (0.59) | PLAUPKMLIG1 | |
| SCHEMBL9373389 | 0.63 | PKM (0.70) | PLAUPKMLIG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |